Last reviewed · How we verify
Carvedilol 12.5 MG
At a glance
| Generic name | Carvedilol 12.5 MG |
|---|---|
| Also known as | Nucleos(t)ide Analogues, Carvipress 12.5 mg |
| Sponsor | Beijing Friendship Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cardiac Changes in Early Parkinson's Disease: A Follow up Study (PHASE2)
- Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients (PHASE4)
- Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices (PHASE4)
- CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (PHASE3)
- CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound (NA)
- Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis. (NA)
- Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices (NA)
- Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol 12.5 MG CI brief — competitive landscape report
- Carvedilol 12.5 MG updates RSS · CI watch RSS
- Beijing Friendship Hospital portfolio CI